What advantage did the production of monoclonal antibodies using hybridoma technology leverage, considering the options: the ability of myeloma cells to live forever in tissue culture, myeloma cells secreting antibodies of known specificity, and the characteristic of antigen-activated B cells to live forever in tissue culture?